Press Releases


Latest News


Adamas Reports Third Quarter 2015 Financial Results
Nov 12, 2015 | Financial Releases

Adamas Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference
Oct 27, 2015 | General Releases

Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait
Oct 12, 2015 | General Releases

Adamas Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Aug 27, 2015 | General Releases

Adamas Reports Second Quarter 2015 Financial Results
Aug 11, 2015 | Financial Releases

Adamas Completes Recruitment of Its Phase 3 EASE LID Study Evaluating ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated With Parkinson's Disease
Jul 9, 2015 | General Releases

Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program
Jul 7, 2015 | General Releases

Adamas Pharmaceuticals to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
Jun 24, 2015 | General Releases

Adamas Announces Additional Findings From Its Phase 2/3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease
Jun 15, 2015 | General Releases

Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment
Jun 11, 2015 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10